10-K: Intra-Cellular Therapies to be Acquired by Johnson & Johnson for $14.6 Billion

Intra-Cellular Therapies (ITCI) has entered into a definitive agreement to be acquired by Johnson & Johnson for $132 per share in cash, valuing the company at approximately $14.6 billion.

Summary

• Intra-Cellular Therapies, Inc., a biopharmaceutical company, is set to be acquired by Johnson & Johnson for $132 per share in cash, a deal valued at approximately $14.6 billion.
• The acquisition is expected to close this year, pending stockholder and regulatory approvals.
• The company's commercial product, CAPLYTA, is approved for the treatment of schizophrenia and bipolar depression in adults.
• CAPLYTA's efficacy in schizophrenia was demonstrated in two placebo-controlled trials, showing statistically significant separation from placebo on the PANSS total score.
• CAPLYTA's efficacy in bipolar depression was demonstrated in two placebo-controlled trials, showing statistically significant improvements over placebo for the change from baseline in the MADRS total score.
• Lumateperone is in clinical development as a novel treatment for MDD, with positive topline results from Phase 3 clinical trials, Study 501 and Study 502.
• In December 2024, the company submitted a supplemental new drug application (sNDA) to the FDA for potential regulatory approval of lumateperone for MDD in adults, as adjunctive therapy to antidepressants.
• The FDA accepted the sNDA for review in the first quarter of 2025.
• The company is also conducting an additional global Phase 3 clinical trial, Study 505, evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
• The company completed Study 304, evaluating lumateperone for the prevention of relapse in patients with schizophrenia and announced topline results in November 2024.
• The study showed that time to relapse during the double-blind treatment phase was significantly longer in patients receiving lumateperone compared to those receiving placebo (p=0.0002).
• The company is also developing ITI-1284-ODT-SL for the treatment of generalized anxiety disorder, psychosis in patients with Alzheimer's disease and agitation in patients with Alzheimer's disease.
• Patient enrollment is ongoing in Phase 2 studies evaluating ITI-1284-ODT-SL for these indications.
• The company is also developing ITI-1500 program focused on the development of novel non-hallucinogenic psychedelics, with lead compound ITI-1549 currently being evaluated in IND enabling studies.
• The company has a PDE1 program, with lead compound lenrispodun, in Phase 2 clinical trial evaluating improvements in motor symptoms, changes in cognition, and inflammatory biomarkers in patients with Parkinsons disease.
• The company discontinued the ITI-333 program.
• As of February 1, 2025, the company employed 860 full-time employees.
• The company had cash, cash equivalents, investment securities and restricted cash totaling $1.0 billion at December 31, 2024.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the acquisition agreement, strong cash position, and positive clinical trial results. However, the ongoing net losses and competition temper the overall outlook.

Positives

• The acquisition by Johnson & Johnson provides significant value to ITCI's shareholders.
• CAPLYTA has demonstrated efficacy in treating schizophrenia and bipolar depression.
• Positive Phase 3 results for lumateperone as an adjunctive therapy for MDD.
• Study 304 showed a significant reduction in relapse risk for schizophrenia patients treated with lumateperone.
• The company has a diverse pipeline of product candidates in clinical development.
• The company has a strong cash position of $1.0 billion as of December 31, 2024.

Negatives

• The acquisition is subject to customary closing conditions, including regulatory and stockholder approvals, which may not be obtained.
• The company has experienced significant net losses since inception and expects to continue to incur net losses.
• The company relies on third-party manufacturers for the production of CAPLYTA and its product candidates.
• The company faces intense competition from other pharmaceutical and biotechnology companies.
• The company discontinued the ITI-333 program.

Risks

• The acquisition may not be completed or may be delayed.
• The company may not obtain regulatory approval for lumateperone for MDD or other indications.
• The company may not be able to successfully commercialize CAPLYTA or its other product candidates.
• The company may require additional funding, which may not be available on acceptable terms.
• The company relies on third parties to conduct clinical trials and perform data collection and analysis.
• The company is subject to ongoing regulatory obligations and restrictions.
• CAPLYTA and its product candidates may not gain or maintain acceptance among physicians, patients, or the medical community.
• The company may be unable to adequately protect its proprietary rights.
• The company faces intense competition from other pharmaceutical and biotechnology companies.
• The company is subject to complex and evolving U.S. federal and state, and foreign laws and regulations, imposing obligations on how we collect, use disclose, store and process personal data.
• Public health threats could have a material impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and non-clinical studies.

Future Outlook

The company expects the acquisition by Johnson & Johnson to close this year, subject to customary closing conditions. The company intends to continue to commercialize CAPLYTA and advance its clinical development programs.

Industry Context

The announcement comes amid increasing M&A activity in the biopharmaceutical industry, as larger companies seek to bolster their pipelines and commercial portfolios. The focus on CNS disorders reflects the growing recognition of unmet needs in this therapeutic area.

Comparison to Industry Standards

• CAPLYTA competes with branded products like Vraylar (AbbVie), Rexulti (Otsuka Pharmaceutical), and Lybalvi (Alkermes), as well as generic antipsychotics.
• The company's success will depend on its ability to differentiate CAPLYTA in terms of efficacy, safety, and cost-effectiveness compared to existing treatments.
• The company's pipeline programs, such as ITI-1284 and lenrispodun, target areas with significant unmet medical needs, but face competition from other companies developing novel therapies.

Legal Proceedings

• The company is involved in patent litigation with generic drug manufacturers seeking to market generic versions of CAPLYTA.
• The company entered into a settlement agreement resolving the patent litigation against Sandoz Inc., granting Sandoz the right to sell generic versions of CAPLYTA in the United States beginning July 1, 2040, or earlier under certain circumstances.
• The patent litigation that the company brought against the other ANDA Filers remains pending in the U.S. District Court for the District of New Jersey.

Stakeholder Impact

• Shareholders will receive $132 per share in cash upon completion of the acquisition.
• Employees face uncertainty regarding their roles following the acquisition.
• Patients may benefit from increased access to CAPLYTA and other ITCI products under Johnson & Johnson's ownership.
• The acquisition could impact the company's relationships with suppliers and other business partners.

Next Steps

• Obtain stockholder approval for the acquisition.
• Receive required regulatory approvals for the acquisition.
• Continue commercialization of CAPLYTA.
• Advance clinical development programs for lumateperone and other product candidates.

Key Dates

Keywords

lumateperone, CAPLYTA, MDD, schizophrenia, bipolar depression, clinical trials, FDA, Johnson & Johnson, acquisition, ITI-1284, ITI-1500, lenrispodun, pharmaceutical, biopharmaceutical